TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06583265
Drug: Observational
Approvals — FDA: no, EMA: no, PMDA: no
Description: To observe if endometrial compaction ≥ 5% in down regulated FET cycles increases clinical pregnancy rate.
Study: NCT06583902
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with an absolute deficiency (ferritin ≤100 μg/L) or functional deficiency (ferritin ≤ 300 μg/L with transferrin saturation ≤20%) receive iron supplementation, through a single administration of an iron preparation for intravenous use administered according to the doses present in the technical data sheet.
Study: NCT06584045
Drug: Calculus bovis sativus (CBS)
Normalized name: Mycobacterium bovis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT05192304
Drug: TPN-672
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of TPN-672 maleate tablet
Study: NCT04895345
Drug: TQB2450
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
Study: NCT06629116
Drug: Patients with AIS receive intravascular therapy, and within 10 minutes after the surgery, they are administered 100ml of 20% human albumin intravenously (infused within 30 minutes).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whether to administer albumin to AIS patients after intravascular thrombectomy and reperfusion.
Study: NCT06630572
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to receive Placebo for 14 days
Study: NCT06206915
Drug: XZ120 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: in Part One：XZ120 monotherapy, IV, no less than 60min, Q3W dose escalation study: 4 dose group (0.75 mg/m2, 1.5 mg/m2, 2.25 mg/m2, 3.0 mg/m2) Dose expansion study: MTD dose
Study: NCT05761223
Drug: Phase Ib dose-expansion of FB849 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: At recommended dose for expansion cohort once daily
Study: NCT04985318
Drug: Cablivi®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention with Cablivi® take place outside of the study
Study: NCT05393895
Drug: CSF-1
Normalized name: CSF-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 6 weeks
Study: NCT05393895
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop bilaterally twice daily for approximately 6 weeks
Study: NCT06712654
Drug: AP306 75mg TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving orally AP306 75mg (one tablet), three times a day
Study: NCT06712654
Drug: AP306 100mg TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving orally AP306 100 mg (one tablet), three times a day.
Study: NCT06712654
Drug: AP306 125mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving orally AP306 125 mg (one tablet), three times a day, among which one is a placebo tablet
Study: NCT06712654
Drug: AP306 150mg BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving orally AP306 150 mg (one tablet), three times a day, among which one is a placebo tablet
Study: NCT06712654
Drug: Placebo TID
Approvals — FDA: no, EMA: no, PMDA: no
Description: receiving orally one placebo tablet of AP306, three times a day
Study: NCT06713057
Drug: Cyclophosphamide+Pemetrexed+5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV or PO
Study: NCT06713057
Drug: Cyclophosphamide+Doxorubicin+5-Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV or PO
Study: NCT06713057
Drug: Doxorubicin + Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or PO
Study: NCT06713057
Drug: Doxorubicin + Cyclophosphamide + Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or PO
Study: NCT06713057
Drug: Docetaxel + Doxorubicin
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV or PO
Study: NCT06713057
Drug: Paclitaxel + Doxorubicin
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV or PO
Study: NCT05515120
Drug: Acenocoumarol Oral Tablet
Normalized name: acenocoumarol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: It was adopted an equal allocation of patients to each treatment (i.e., 1:1 randomization)
Study: NCT06714032
Drug: TCM plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
Study: NCT06714032
Drug: TCM placebo plus conventional drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were treated according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
Study: NCT00002138
Drug: Tecogalan sodium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06714084
Drug: maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: one years of maintenance therapy with carbonilumab alone will be implemented to patients with advanced cervical cancer receiving standard concurrent chemoradiotherapy
Study: NCT06057545
Drug: Envarsus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment sequence: 4 weeks prolonged-release tacrolimus (Envarsus®) once daily
Study: NCT06060587
Drug: ADT
Normalized name: Radtue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior to randomization as part of standard of care.
Study: NCT00001023
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00001023
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05763004
Drug: IOS-1002 + KEYTRUDA® (pembrolizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination therapy
Study: NCT04891354
Drug: PDNO
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PDNO consists of propylene glycol (1,2-propanediol, PD) chemically combined with NO (to be donated). The drug substance is formulated as an inherent mixture of 4 structure analogues. The mixture consists of an equilibrium of the 2 regioisomers 1-(nitrosooxy) propan-2-ol and 2-(nitrosooxy) propan-1-ol. In addition, each regioisomer is a racemic mixture.
Study: NCT05268172
Drug: IFN-γ and CIK cells, Tcm cells or CAR T cells
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 50ng/ mL IFN-γ solution was prepared, and the required volume of IFN-γ solution was calculated according to the final concentration of 5ng/ mL according to the volume of pleural fluid or ascites of the patient. CIK cells were injected 1.0-2.0×109 on the second day and review three days later.T cells and CAR T cells were selected sequentially according to the re-examination of pleural fluid or ascites.
Study: NCT05349864
Drug: PF-07284890 Treatment C
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-07284890 tablet after high fat meal
Study: NCT05507463
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05835180
Drug: TVB-2640 - 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVB-2640 -50 mg administered orally once daily
Study: NCT06284668
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing oocyte retrieval were given 5ml 0.9% saline before anesthesia and surgery
Study: NCT05954169
Drug: SHR4640
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 single-dose
Study: NCT04700046
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
Study: NCT05215834
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1. Remimazolm and Remifentanil (RR group): anesthesia was induced with remimazolam 6 mg/kg/h by continuous intravenous (IV) infusion and with the effect-site concentration of remifentanil 4 ng/ml and until the loss of consciousness (LoC), followed by remimazolam 1-2 mg/kg/h and remifentanil 3 ng/ml until the end of surgery.~2. Propofol and Remifentanil (PR group), anesthesia was induced with the effect-site concentration of propofol of 6.0 μg/ml and remifentanil 4 ng/ml, and until the loss of consciousness (LoC), followed by the effect-site concentration of propofol of 2-4 μg/ml and remifentanil 3 ng/ml until the end of surgery.
Study: NCT06288321
Drug: Microdrop Mydrin-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdrop Mydrin-P consists of around one third of the standard Mydrin-P drop size. Drop volume measurement was performed using a precision weight scale (Sartorius) with accuracy up to 0.001g. The microdrop administration was conducted via attachment of a 16 gauge needle to a 1ml syringe.
Study: NCT06288321
Drug: Standard Mydrin-P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Mydrin-P is the standard mydriatic used for retinopathy of prematurity exam as per our local usual practice.
Study: NCT06417489
Drug: Sequential treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin, the dose from the first to second week is 500mg bid, and the dose from the third to fourth week is 1000mg bid. If the maximum dose of metformin cannot be tolerated, the researcher shall increase the dosage according to the patient\&#39;s tolerance situation. The minimum dose is 1000mg/day. After the fourth week of treatment, blood glucose levels were measured. For those whose blood glucose levels did not meet the standard (fasting blood glucose (FPG)\&gt;7mmol/L, postprandial blood glucose (PPG)\&gt;10mmol/L), 10 mg qd of Henagliflozin Prolinewas sequentially added. If the blood glucose levels did not meet the standard after 4 weeks of treatment (FPG\&gt;7mmol/L, PPG\&gt;10mmol/L), 100 mg qd of Ruigeliflozin was added
Study: NCT06292650
Drug: ZM-02-L
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: rAAV-PsCatCh2.0 intravitreal injection of low dose
Study: NCT04864509
Drug: Melatonin 10 MG
Normalized name: melatonin 10 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nightly dose
Study: NCT04864509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nightly dose
Study: NCT05975294
Drug: 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA device of 100 ml volume containing 80 mg of nalbuphine ,180 mg ketorolac, 24mg dexamethasone, 16 mg danset and normal saline at a rate of 2 ml/h.
Study: NCT05211154
Drug: Diclofenac Potassium 50Mg/Pkt Oral Pwdr
Normalized name: DICLOFENAC POTASSIUM 50MG/PKT ORAL PWDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment for an acute, moderate to severe migraine attack
Study: NCT02989012
Drug: GanMaoKangNing Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day, 2 bags each time.
Study: NCT02989012
Drug: Analogous GanMaoKangNing Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 times a day, 2 bags each time.
Study: NCT04786795
Drug: Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets
Normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the control group takes Oryz-aspergillus Enzyme both Pancreatin Tablet and Ursodeoxycholic Acid Tablets. They were registered before medication and on days 14 and 28 after medication, and gastrointestinal symptoms were assessed at each follow-up visit
Study: NCT05794750
Drug: AK104 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study: NCT05794750
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Eligible subjects will receive short-course radiotherapy (SCRT), IMRT/VMAT, pelvic 25Gy/5f/1 week. Two weeks after the end of treatment, subjects continued to receive neoadjuvant chemotherapy combined with immunotherapy regimen for 4 cycles: AK104 10 mg/kg, intravenous infusion every 3 weeks (Q3W), plus CAPOX (capecitabine: 1000mg/m2, bid, po, d1-14, oxaliplatin: 130mg/m2, ivgtt, d1), Q3W. Neoadjuvant therapy was assessed 2 weeks after the end of neoadjuvant therapy, and TME surgery was performed 4 weeks after the end of neoadjuvant therapy (R0 surgery was performed).
Study: NCT04908605
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Every patient will be given melatonin 5 mg tablet
Study: NCT04908605
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every patient will be given a matching placebo tablet
Study: NCT06397807
Drug: Enteral analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioids, NSAIDs or acetaminophen will be prescribed if necessary.
Study: NCT05130060
Drug: Trifluridine and Tipiracil Hydrochloride
Normalized name: tipiracil / trifluridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT05181865
Drug: 1 mg/kg IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: N = 1
Study: NCT05181865
Drug: 3 mg/kg IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: N = 3-6
Study: NCT05181865
Drug: 10 mg/kg IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: N = 3-6
Study: NCT05181865
Drug: 20 mg/kg IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: N = 3-6
Study: NCT05181865
Drug: 30 mg/kg IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: N = 3-6
Study: NCT05181865
Drug: RP2D, IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic Cancer N = 30
Study: NCT05181865
Drug: RP2D, IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric Cancer (Including GEJ) N = 30
Study: NCT05181865
Drug: RP2D, IV FL-301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Solid Tumors N = 30
Study: NCT05869643
Drug: High-dose STP0404 (Pirmitegravir)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily, oral capsule taken after breakfast
Study: NCT05869643
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsule, taken orally once daily after breakfast
Study: NCT06027099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet three times a day for 5 weeks after surgery
Study: NCT05787925
Drug: Topical corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26 patients will administrate topical corticosteroid: triamcinolone acetonide 1% oral gel Kenacort-A Orabase three times daily for 8 week that will be applied after meals and at night with avoidance of foods and drinks for 30 minutes after the application
Study: NCT06629376
Drug: Pegylated Recombinant Candida Utilis Uricase for Injection
Normalized name: antihemophilic factor (recombinant) pegylated Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: According to the dosage requirements of each experimental group, intravenous infusion should be administered for at least 2 hours each time
Study: NCT05030311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT04749433
Drug: [11C]CPPC Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of \[11C\]CPPC (370 megabecquerel (MBq) (X±1 mCi)) intravenously and subsequent positron emission tomography (PET) scan.
Study: NCT05905367
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Symptom-inhibited IV fentanyl induction
Study: NCT04109118
Drug: BZD discontinuation protocol
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
Study: NCT05788094
Drug: Artemether-Lumefantrine plus Tafenoquine (450 mg adult dose)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Artemether-Lumefantrine will be given at a standard dose of 20/120 mg twice daily for three days. (AL will be purchase from Novartis Pharma Services AG- Lichtstrasse 35, CH-4056 Basel, Switzerland.)~* Tafenoquine KODATEF® 100 mg film-coated tablets will be purchased from Biocelect (Suite 5.02, Level 5, 139 Macquarie Street, Sydney NSW, 2000 Australia), 450 mg (4 1/2 tablets) will be given.
Study: NCT06216821
Drug: standard DAPT
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard DAPT with aspirin and a P2Y12 inhibitor for 12 months after DES implantation.
Study: NCT04789850
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral for 360 days
Study: NCT06216821
Drug: OPT-CAD score guided DAPT de-escalation
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: De-escalation DAPT at 3 months for moderate to high risk patients and de-escalation DAPT at 1 month for low risk patients.
Study: NCT04891133
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg placebo (2 tablets of 2 mg) once daily
Study: NCT05039944
Drug: FOLFIRI Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRI is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Study: NCT05039944
Drug: FOLFOX Protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX is administered intravenously at the standard dose recommended by the guidelines(Q2W).
Study: NCT05096117
Drug: ASP8062
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
Study: NCT05096117
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x per day for 6 weeks
Study: NCT05886582
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drug
Study: NCT04727320
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo, once a day, one tablet at a time for 6 months
Study: NCT05001282
Drug: ELU001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic-acid functionalized C'Dot-Drug-Conjugate (FA-CDC)
Study: NCT05807880
Drug: The combination treatment of anlotinib, penpulimab and capecitabine.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive the combination treatment of anlotinib, penpulimab and capecitabine every three weeks until PD or intolerance to drug toxicity. For each cycle, patients receive anlotinib 10mg, po, qd from day 1 to day 14, penpulimab 200mg, iv in day 1, and capecitabine 650mg/m2, po, bid.
Study: NCT05617651
Drug: IY-NT-R
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilaprazole 10mg
Study: NCT06162351
Drug: PLX038
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study treatment will be at a dose of 1730mg/m2 IV infusion on Day 1 of each cycle Q3W (every 21 days, 1 cycle = 1 injection).~Patients with a clinical benefit could be treated as long as study is ongoing. Patients are followed from inclusion until documented disease progression, withdrawal of consent, or death.
Study: NCT06466473
Drug: Phenytoin (Ascoli)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin 50mg chewable tablets
Study: NCT06466473
Drug: Phenytoin (Vega Baja)
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin 50mg chewable tablets
Study: NCT04218539
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg Diphenhydramine
Study: NCT04589611
Drug: Placebo (single dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo during the initial surgical intervention
Study: NCT04589611
Drug: Placebo (two doses)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One dose of placebo during the initial surgical intervention. A second dose will be administered during the second surgical intervention.
Study: NCT05803590
Drug: Green tea mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: effictive against caries and periodontal diseases
Study: NCT05623995
Drug: PCSK9 inhibitor
Normalized name: PCSK9 inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..
Study: NCT05623995
Drug: Statin
Normalized name: Statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline recommended statin therapy.
Study: NCT05964257
Drug: normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline will be administered intramuscularly to the bilateral masseter muscles on Visit 2.
Study: NCT05944237
Drug: HTL0039732 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTL0039732 Capsules will be administered orally to fasted participants, although an exploration of food effects may be performed as a single dose at Cycle 0. A single dose will be administered between 3 and 9 days prior to commencement of Cycle 1. From Cycle 1 Day 1, HTL0039732 will be administered on a once daily (QD) schedule. Each administration cycle will consist of 21 days with no break between cycles. Participants may initially receive up to 18 cycles but may continue for a further 18 cycles if they are deemed to be benefitting.
Study: NCT05576662
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours